The Semliki Forest virus (SFV) vector is an RNA-based suicide expression vector that has been used experimentally for tumour therapy. Recently, a new enhanced vector pSFV10-E has been developed that expresses foreign genes at levels up to 10 times higher than the original vector. Interleukin-12 (IL-12), an immunomodulatory cytokine, plays a key role in the induction of T-helper1 responses. The two IL-12 gene subunits were cloned from mouse splenocytes and inserted into the pSFV10-E and pSFV10 (nonenhanced) vectors. Both constructs expressed and secreted biologically active murine IL-12. Administration of high titre rSFV10-E-IL12 particles intratumourally to treat implanted K-BALB tumours in BALB/c mice demonstrated complete tumour regression in comparison to control or rSFV10-IL12 treated groups. High titre rSFV10-E-IL12 particles were also effective in the CT26 tumour model. Histological and immunohistochemical studies revealed tumour necrosis in addition to aggressive influx of CD4+ and CD8+ T cells and other immune cells. Furthermore, inhibition of primary tumour growth and lung metastases of a metastatic (4T1) tumour model indicated the potential of high titres of rSFV10-E-IL12 particles as an efficient antitumour therapeutic agent.
Introduction
Research on cancer gene therapy has largely focused on induction of apoptosis in cancer cells or on stimulation of immune mechanisms to eliminate cancer cells. Many investigations have used viral vectors such as retro, adeno, adeno-associated, or alphavirus vectors. Alphavirus vectors demonstrate high-level expression of heterologous proteins in a broad host range of cells [1] [2] [3] [4] [5] and have been shown to induce apoptosis in infected cells. 6, 7 Semliki Forest virus (SFV), an alphavirus, is an enveloped positive-sense RNA virus of the family Togaviridae; it has been developed into a transient RNA-based suicidal expression vector system. 8 This system consists of a vector in which foreign genes can be expressed, and two helper vectors that encode the structural protein genes. Cotransfection of all three vectors into cells results in release of recombinant virus-like particles (VLPs) coding for the foreign gene. 9 The SFV vector system has several advantages over other vector systems in its broad host range and inherent ability to induce apoptosis. 10 SFV vectors have been successfully used to induce in vivo expression of a number of genes such as cytokines, [11] [12] [13] tumour-associated antigens (TAA), 13, 14 and vaccine antigens, 15, 16 and to deliver therapeutic genes to the central nervous system. 17 It has been shown that recombinant SFV (rSFV) particles can efficiently infect tumour cells and that intratumoural treatment with rSFV particles results in the induction of p53-independent apoptosis leading to significant tumour inhibition. However, in order to achieve complete regression in at least a proportion of treated mice, multiple treatments at relatively high doses are needed. 7 SFV vectors expressing the cytokine interleukin-12 (IL-12) induce tumour regression mainly by inhibition of angiogenesis. 18 Clinical trials (Phase I and II) have been planned to use liposomeencapsulated SFV vectors expressing IL-12 in the treatment of several tumours, including glioblastoma multiforme. 19 These and other studies have indicated that the SFV vector is an effective tumour therapy agent. 10 An enhanced SFV expression vector system, pSFV10-E, has been developed which has been shown to produce up to 10 times more foreign protein than the original SFV vector. This vector contains the N-terminal 34 amino acids of the SFV capsid protein followed by the foot and mouth disease virus (FMDV) 2A cleavage sequence ( Figure 1 ). The capsid enhancer drives the enhanced expression of the foreign genes 20 and the FMDV protease cleaves the expressed protein from the capsid enhancer.
Immuno-gene therapy with cytokines is one of the strategies being developed for the activation of immune cells to enhance antitumour responses. Previous experiments using SFV vectors expressing cytokines have given promising results. [11] [12] [13] It has been shown that the amount of IL-12 available at the tumour site is critical for tumour regression. A major drawback of systemic treatment with IL-12 is its short plasma half-life and the toxicity associated with high systemic concentrations. However, concentration of cytokine at the tumour site increases therapeutic efficacy and reduces the systemic side effects. 21, 22 The cytokine IL-12 is a disulphide linked heterodimeric protein, comprising a 35 kDa subunit and a 40 kDa subunit to form a biologically active p70 complex. It is produced by antigen-presenting cells such as dendritic cells, macrophages, B-cells, and possibly other accessory cells, after exposure to infectious agents. IL-12 induces the differentiation of T-helper1 (Th1) CD4+ cells, which are inducers of IFN-g production. 23 It has been reported that tumour treatment using IL-12 is associated with the expression of the cytokine IFN-g and chemokines such as IP-10 at the tumour site, inducing the antitumour effect through a direct toxic effect on the tumour cells or by activating potent antiangiogenic mechanisms. 24 The induced antiangiogenic mechanisms are complex and dependent both on the direct effect of the proinflammatory cytokines/chemokines on endothelial cells and the recruitment of effector NK and T-cells. IL-12-induced specific immunological memory has been reported, making IL-12 a promising candidate for permanent and specific tumour eradication. 25 In this study, we constructed pSFV10-IL12 (normal expression of murine IL-12) and pSFV10-E-IL12 (enhanced expression) vectors and examined the antitumour effect of these constructs. Three different tumour models were utilised to demonstrate the consistency of IL-12 therapeutic efficacy. K-BALB cells are murine sarcoma virus transformed mouse fibroblasts that overexpress the K-ras oncogene and form aggressive localized syngeneic tumours in immunocompetent BALB/c mice on subcutaneous (s.c.) injection. 26, 27 CT26 cells are murine colon adenocarcinoma cells which form localized tumours of low immunogenicity in BALB/c mice after s.c. injection. [28] [29] [30] To examine the effect of treatment on a metastasizing tumour model, we have selected the highly malignant, spontaneously metastasising 4T1 mouse mammary carcinoma model that also readily develops into tumours on s.c. implantation. [31] [32] [33] Complete and permanent in vivo tumour regression was found in all three tumour models treated with high titre rSFV10-E-IL12 particles, and in the case of the 4T1 model, inhibition of metastasis formation also occurred. Figure 1 The SFV vectors. The standard SFV vector SFV10 and the enhanced vector pSFV-E, both expressing the IL-12 subunits p40 and p35 from separate 26S promoters. The plasmid used to transcribe the vector RNA from the SP6 promoter (after linearization with SpeI) is shown on the left and the transcribed RNA (incorporating the enhancer element (enh) in the case of rSFV-E) on the right. Recombinant VLPs were produced using the split helper system. 9 The nucleotide sequence of the enhancer element is shown in the inset. Italics indicate the Kozak and methionine initiation sequences, standard typeface codons for amino acids 2-34 of the capsid protein, and bold codons for17 amino acids of the 2A protein; cleavage occurs before the last amino acid (proline).
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Results

Comparative analysis of IL-12 expression levels
The difference in expression levels of murine IL-12 between the two vector constructs pSFV10-E-IL12 and pSFV10-IL12 ( Figure 1 ) was examined by qualitative and quantitative assays in BHK-21 and K-BALB cells. By immunohistochemistry, cells infected with rSFV10-E-IL12 VLPs were more intensely stained due to high-level expression compared to rSFV10-IL12-infected cells (Figure 2 ). This was confirmed by an ELISA assay of supernatants from infected BHK-21 and K-BALB cells.
The expression levels of IL-12 in BHK-21 cells by rSFV10-E-IL12 were found to be 3-4 times higher than rSFV10-IL12 VLPs, whereas in K-BALB cells, a 10-fold difference was found ( Figure 3 ). As expected, mock-infected and rSFV10-EGFP-infected control BHK-21 and K-BALB cells showed no IL-12 expression. Expression levels of IL-12 were broadly similar to those obtained for adeno 34 and herpes 35 vectors expressing the same cytokine.
Biological activity of secreted murine IL-12
Biologically active IL-12 induces T cells to secrete interferon-g (IFN-g). An ELISA measured the production of IFN-g from supernatants of murine splenocyte cultures 24 h after stimulation with supernatants of VLP-infected BHK-21 cells or K-BALB cells. This showed that supernatants of such infected BHK-21 and K-BALB cells, containing IL-12, stimulated splenocytes to produce similar levels of IFN-g to the positive Concavalin A (ConA)-treated control ( Figure 4 ). These results confirmed the expression and secretion of biologically active IL-12 from both rSFV10-E-IL12 and rSFV10-IL12 vectors. However, the stimulation of IFN-g was not directly related to the amount of IL-12 present in the cell supernatants; this may reflect a quantal production of IFN-g on IL-12 stimulation at a threshold level.
Treatment of K-BALB, CT26, and 4T1 tumours using rSFV particles
Initially, experiments were performed to optimize the amount of IL-12 available at the tumour site by varying the titres of VLPs administered. K-BALB tumours were treated with six injections of rSFV10-IL12 or rSFV10-E-IL12 VLPs at 4 Â 10 7 , 4 Â 10 8 , and 4 Â 10 9 IU in 50 ml/ dose, whereas CT26 and 4T1 tumours were treated only with a titre of 4 Â 10 9 IU ( Figure 5 , Table 1 ). An average tumour diameter of 4 mm was reached at 4 and 6 days postinduction of K-BALB, or CT26, and 4T1 tumours, respectively. When K-BALB tumours were treated with a 4 Â 10 7 IU/dose of rSFV10-E-IL12, one mouse showed complete tumour regression at day 19 but average tumour growth did not show a statistically significant difference compared to either the control TNE buffer or rSFV10-EGFP-treated groups (Table 1) . For K-BALB tumours treated with 4 Â 10 8 IU/dose of rSFV10-E-IL12, three out of six mice showed complete tumour regression and increased median survival time compared to the controls (Table 1) . Finally, all six mice bearing K-BALB tumours showed complete tumour regression when treated with six intratumoural injections of 4 Â 10 9 IU ( Figure 5a , Table 1 ). None of the rSFV10-IL12-treated mice showed regression, and there was no overall significant growth inhibition compared to the TNE- Tumour regression by rSFV expressing IL-12 CP Chikkanna-Gowda et al treated group. In these experiments, rSFV10-EGFP and rSFV-IL12 showed some inhibitory effect on tumour growth during the treatment stage, but overall had no significant effect. This initial slower tumour growth rate may be due to the inherent ability of rSFV VLPs to induce apoptosis in tumour cells. 10 Based on these results for K-BALB cells, treatment of CT26 tumours was carried out using six doses of high titre (4 Â 10 9 IU in 50 ml/dose) rSFV10-E-IL12 VLPs; this dose induced complete tumour regression in all six treated mice ( Figure 5b , Table 1 ). All tumours that received rSFV VLPs expressing either EGFP or IL-12 showed tumour swelling during the treatment stage, which related to intratumoural necrosis, inflammation, and oedema. 30 The K-BALB and CT26 tumour regressed mice were monitored for 3 months to ensure no tumour regrowth, indicating that the regressions were complete.
Since the treatment efficacy of the rSFV10-E-IL12 replicon was verified using two different localized tumour models, we next examined its potential to inhibit the growth of established lung metastases in the 4T1 mammary tumour model. Established s.c. 4T1 tumours on the right abdominal flank of BALB/c mice were treated with six injections of 4 Â 10 9 IU/dose in 50 ml on alternate days. Four out of six mice showed complete tumour regression between days 18 and 22 (Table 2 ) and the remaining two mice grew tumours at the same rate as control groups during the post-treatment period. All control (TNE and rSFV10-EGFP) and IL-12-treated tumours were sampled for histopathology and immunohistochemistry when the size reached 15 mm diameter (around day 22). Local spread of 4T1 tumour nodules was noted in control mice after repeated injections.
rSFV10-E-IL12 therapy reduces the number of 4T1 lung metastases
Following s.c. injection, 4T1-breast carcinoma cells formed solid tumours of 4 mm diameter by day 6 postinduction and frequent lung metastases by day 22 postinduction. A large difference in numbers of lung metastases between the rSFV10-E-IL12 and control treated groups was found when the lungs were examined at day 22 post tumour induction. The average number of grossly visible tumour nodules in the TNE and rSFV10-EGFP-treated lungs were 16 and 13.2, respectively, compared to the IL-12-treated groups, which had an average of 1.5 (Table 2) . These findings were supported by histological studies (below). Using the clonogenic assay, the number of 6-thioguanineresistant colonies in the lungs of the 4T1 tumour-bearing Tumour regression by rSFV expressing IL-12 CP Chikkanna-Gowda et al BALB/c mice confirmed the extent of 4T1 lung metastases ( Table 2 ). The lungs of tumour-bearing mice that received TNE or rSFV10-EGFP had a mean of 3 Â 10 4 metastatic colonies. However, the lungs of the rSFV10-E-IL12-treated animals with a mean of 3 Â 10 3 metastatic colonies showed significantly less than both control groups (Table 2 ). These results indicate that the treatment of 4T1 tumours with rSFV10-E-IL12 is associated with increased survival time, which results from inhibition of both primary 4T1 tumour growth and the growth of metastases. The observation that no metastatic colonies were present in the lungs of complete tumour regressed mice (four out of the six treated mice) indicates a correlation between tumour size and the number of metastatic colonies for each mouse, which is consistent with other studies of the 4T1 tumour model ( Table 2) . 33 
Serum levels of antiangiogenic factor IP-10
The inducible protein-10 (IP-10), a chemokine, is known to mediate the antiangiogenic activity of IL-12.
24 Serum of K-BALB tumour-bearing mice was collected 3 days following the sixth treatment to estimate the serum concentration of IP-10 by ELISA ( Figure 6 ). The average IP-10 concentration in IL-12-treated serum samples was found to be significantly higher than in TNE or EGFP control groups, with the enhanced vector inducing significantly more IP-10 than the standard vector.
Tumour pathology and immunohistochemistry
K-BALB tumours treated with TNE were composed of polyhedral and spindle-shaped cells characterized by well-defined cell borders and frequent bizarre mitotic forms. Small numbers of neutrophils were sparsely distributed between the tumour cells (Figure 7a ). Necrosis and haemorrhage with oedema, neutrophils, macrophages, lymphocytes, and plasma cells in the surrounding connective tissue were present at the Average tumour diameter for each group was calculated at the median survival time (7standard error). e The probability is based on the average tumour diameter compared to that of the TNE-treated (control) groups over the survival time of the mice. The cellular response and tumour microvasculature in IL-12 and mock-treated K-BALB and CT26 tumours were further examined using immunohistochemistry. Higher numbers of CD4+ (MHC class II restricted) and CD8+ (MHC class I restricted) cells were located in perivascular spaces at the margins of IL-12-treated tumours than in those treated with TNE (Figure 7g, h ). For most of the IL-12-treated tumours, numbers of CD4+ cells exceeded those of CD8+ cells, but overall the quantitative difference was not significant (data not shown). Using anti-CD31, an antibody specific for vascular endothelial cells, mock-treated K-BALB tumours showed a welldefined capillary network uniformly distributed between the tumour cells (Figure 7i ). Vascular endothelial cells in IL-12 treated tumours were restricted to the non-necrotic areas of the tumours. These results indicate a cumulative antitumour effect of the IL-12-expressing vector, which may involve several mechanisms.
Discussion
In this study, we have shown that intratumoural treatment with SFV vectors expressing IL-12 effectively inhibits tumour growth in three murine tumour models. These results confirm those of other studies that have used IL-12-expressing SFV vectors for the treatment of The number of 6-thioguanine-resistant 4T1 lung metastasized colonies stained and counted for each mouse. 
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CP Chikkanna-Gowda et al other tumour models, [11] [12] [13] [14] and indeed results obtained for adeno 34 and herpes vectors 35 expressing IL-12. However, we have also shown that a combination of the use of high titre vector preparations and a vector expressing high levels of IL-12 can result in complete tumour regression. This treatment also inhibits the growth of lung metastases in a metastatic tumour model.
The cytokine IL-12 has potential as a tumour therapy agent because of its antitumour and antimetastatic activity. 36 IL-12 promotes the activity and differentiation of T cells and NK cells to induce an aggressive antitumour immune response. In addition, a further antitumour activity of IL-12 is its ability to induce IFN-g production by T cells, which in turn mediates antiangiogenic effects. [23] [24] [25] Previous studies have shown that the amount of IL-12 available at the tumour site is critical for tumour regression, since it determines the number and type of infiltrating leucocytes. 21 It may also mediate the antiangiogenic effect of IL-12, 18 although the relative contribution of these two effects to the antitumour activity of IL-12 is not clear.
The development of pSFV10-E, a new SFV-based expression vector system with enhanced expression of foreign protein (up to 10-fold more than the standard pSFV10 system), has enabled us to enhance IL-12 expression locally at the tumour site. Hence, we To confirm the biological activity and secretion of the expressed protein, we measured the ability of supernatants from vector-infected cells to induce IFN-g production by mouse splenocytes. Since high systemic concentrations of IL-12 have been reported to have lethal toxic effects, 22 it was essential to optimize the IL-12 concentrations used to treat the animals. Complete tumour regression in all three models tested was found in animals treated with the highest dose of rSFV10-E-IL12 VLPs, and the animals remained free of clinical signs, indicating that increased levels of IL-12 at the tumour site induce efficient tumour regression without systemic lethal toxic effects.
It is likely that the potent antitumour activity of the IL-12-expressing SFV vector results from a combination of mechanisms. SFV vectors have an inherent p53-independent apoptosis inducing capability, 6 which has been successfully used to treat tumours in nude mice, 7, 37 and it is likely that this operates also for the vectors used in this study. However, the presence of the enhancer in rSFV10-E-IL12 is unlikely to increase this inherent apoptosis induction since all cells infected by the unenhanced vector undergo apoptosis and the vector does not spread intercellularly. 6, 7, 37 The enhanced ability of this vector to destroy tumour cells must therefore result from the induction of enhanced IL-12 secretion. IL-12 has a potent proinflammatory activity that may contribute to the antitumour effect. Although K-BALB cells are syngeneic with BALB/c mice and are poorly immunogenic, 27 influx of lymphoid cells into the peritumoural tissue following treatment was demonstrated by histopathology. A third antitumour mechanism that may operate is the inhibition of tumour angiogenesis by IL-12, which has been demonstrated in a previous study of tumour treatment by an IL-12-expressing SFV vector. 18 In the present study, the increased levels of the antiangiogenic chemokine IP-10 in the blood of treated mice, allied to the frequent occurrence of thrombosis and haemorrhage in the treated tumours, suggests that inhibition of angiogenesis also played a role in our model system.
The antiangiogenic action of IL-12 may also be responsible for inhibition of the growth of metastases in the 4T1 tumour model, since angiogenesis inhibitors are known to induce tumour cell apoptosis by limiting the supply of nutrients and other cell survival factors derived from endothelial cells. 38 It is also possible that inhibition of the growth of the primary tumour restricts tumour mass so that fewer metastases are formed. However, the latter explanation does not explain the total absence of metastases in animals where the primary tumour had totally regressed.
A phase I/II clinical trial has been proposed for the use of an SFV vector expressing IL-12 for the treatment of glioblastoma multiforme, an incurable human brain tumour, by direct perfusion of the tumour with liposome-encapsulated recombinant particles. 19 In designing this and similar clinical trials, the use of the high titre and high expression recombinant particle system used in the present study should be considered.
Materials and methods
Mice
Specific pathogen-free immuno-competent 4-6-week-old female BALB/c mice were obtained from Harlan (Bicester, UK) and maintained under pathogen-free conditions in accordance with the principles set down in SI 17/94 of the European Union.
Cell culture
The K-BALB (K-ras overexpressing transformed BALB/ 3T3), CT26.WT (colon adeno carcinoma from BALB/c mouse), and 4T1 (metastasing breast carcinoma from BALB/c mouse) tumour cell lines were obtained from ATCC. The K-BALB, CT26, and 4T1 cells were cultured in Dulbecco's minimal essential medium supplemented with 10% foetal bovine serum and antibiotics (streptomycin 100 mg/ml and penicillin 100 U/ml). BHK-21 cells were obtained from ATCC and were propagated in BHK-21 medium supplemented with 5% foetal bovine serum, 10% tryptose phosphate broth, 2 mM L-glutamine, 20 mM HEPES, and antibiotics.
Cloning of murine IL-12 subunits p35 and p40 into pSFV10 and pSFV10-E vectors
To construct pSFV10-IL-12 vectors (Figure 1 ), initially cDNA of IL-12 subunits p35 and p40 was amplified from the total RNA of BALB/c mouse splenocytes using PFU-DNA polymerase. The following primers were used to amplify the dimeric subunits of IL-12, each having (p40, antisense). The p35 and p40 genes were ligated into two separate pSFV10-E vectors using the Quick Ligation Kit (NEB), which resulted in pSFV10-E-p35 and pSFV10-E-p40. The p35 and p40 genes from their respective pSFV10-E constructs were released by HindIII (NEB) digestion and the generated ends of the subunits were blunted using DNA polymerase I large fragment (Klenow, NEB). The pSFV10 vector was linearized using BamHI and the sticky ends blunted and dephosphorylated with shrimp alkaline phosphatase (Roche). Blunted p35 and p40 subunits were ligated into linearized pSFV10 separately to obtain pSFV10-p35 and pSFV10-p40 and the orientation checked. The p35 subunit was then removed together with its subgenomic 26S promoter from the pSFV10-E-p35 and pSFV10-p35. The 26S-p35 fragment was subsequently cloned into the SmaI restriction site just downstream of the p40 subunit in the pSFV10-E-p40 and pSFV10-p40 constructs to obtain the pSFV10-E-IL12 and pSFV10-IL12 constructs (Figure 1 ).
Production of rSFV-IL-12 virus-like particles
The SFV split-helper vector system was obtained from P Liljeströ m (Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden) and VLPs produced as previously described. 9 Briefly, BHK-21 cells An assay for the biological activity of secreted IL-12 from both the rSFV constructs was performed using mouse T cells. Mouse splenocytes were incubated with supernatants (24 h after infection) from mock or rSFV-IL12 VLP-infected BHK-21 or K-BALB cells. Naïve and Concavalin A (ConA) (1 mg/ml)-treated splenocytes were used as controls. The supernatant was collected at 24, 48, and 72 h after infection and an IFN-g assay was carried out. This consisted of an ELISA test using OptEIATM Set Mouse IFN-g (BD Biosciences).
Establishment and treatment of K-BALB, CT26, and 4T1 tumours with rSFV-IL12 VLPs Female 6-8-week-old BALB/c mice were used in all the tumour treatment experiments. Tumours were induced subcutaneously on the right flank of each mouse by injecting 10 6 cells in 100 ml Hank's balanced salt medium with a 29 G 0.5 ml syringe. Tumours were measured daily using a linear caliper and average tumour diameter was calculated as the square root of the product of two perpendicular measurements, assuming spherical shape. 7 The established tumours were treated when the size reached 4 mm diameter. In all tumour treatment experiments, mice were culled once the tumour size reached 10% of body weight (15 mm). Six mice were used in each of the treatment groups. The tumours were treated on alternate days with a total of six intratumoural injections of 50 ml of TNE buffer alone, TNE buffer containing rSFV10-EGFP, 7 rSFV10-E-IL12 or rSFV10-IL12. VLPs were administered at varying titres (4 Â 10 7 , 4 Â 10 8 or 4 Â 10 9 IU/ml). CT26 and 4T1 tumours were treated only with TNE, or 4 Â 10 9 IU/ml rSFV-EGFP or rSFV10-E-IL12 VLPs. Two sets of animals were used for each treatment; the first group was assayed for survival and the second group assayed for pathology, serology, immunohistochemistry, and lung metastases (4T1 tumour model only).
Detection of lung metastases
Lungs were examined for 4T1 metastases as previously described. 33 Briefly, mice were killed at day 24 posttumour induction and the lungs removed for gross examination, histopathology, and clonogenic assay. The right lungs were immersion fixed in formol saline, sliced, and processed to paraffin wax; sections 4 mm thick were cut and stained with haematoxylin and eosin (H&E). The left lungs were treated with Elastase and Liberase blendzymes (Roche) and the cells harvested by filtering through a 70 mm nylon cell strainer. Lung cells were diluted and plated in culture medium containing 60 mM 6-thioguanine (2-amino-6-mercaptopurine, Sigma). The 4T1 cells (which are resistant to thioguanine) were grown for 10-12 days and the clonogenic colonies of 4T1 cells fixed in methanol and stained with crystal violet for quantitation of clonogenic lung metastases.
Pathology and immunohistochemistry
For pathology, K-BALB, CT26, and 4T1 tumours were resected 1 day after the sixth treatment, immersion fixed in formal saline, sliced and processed to paraffin wax; 4 mm sections were cut and stained with H&E.
For immunohistochemistry, K-BALB and CT26 tumours were resected 1 day after the sixth treatment, embedded in Tissue-Tek OCT compound (Fisher scientific), and snap frozen in isopentane. Tumours were sectioned at 6 mm in a cryostat microtome. The sections were used for immunohistochemical staining to detect CD4 and CD8 cells in the tumour. The sections were fixed in ethanol, quenched with 0.3% hydrogen peroxide, blocked in 5% rabbit serum for 30 min at room temperature, and endogenous avidin and biotin blocked using a blocking kit (Vectorstain ABC Kit Elite, Vector Laboratories). The sections were treated with primary antibody, either rat anti-mouse CD4 (1:20, Pharmingen) or CD8 (1:20, Pharmingen) diluted in 5% rabbit serum (Vector Laboratories) at room temperature for 1 h. Secondary antibody and biotinylated rabbit anti-rat antibodies, (1:1000, Vector Laboratories) were used at room temperature for 45 min. For detection of vascular endothelial cells, sections of tumours were labelled using 5% goat serum as blocking buffer, rat anti-mouse CD31 (1:50, Pharmingen) as primary antibody, and biotinylated goat anti-rat IgGs as secondary antibody. The primarysecondary antibody complexes were detected using the Vector Elite ABC standard HRP kit according to the manufacturer's instructions, with DAB as substrate. The sections were washed between each step with PBS and counterstained with haematoxylin. Mouse spleens were used as positive controls; a negative control was used in each assay by substituting the primary antibody with 5% normal rabbit serum. The labelled sections were mounted and observed by light microscopy for positive cells stained brown.
Serum analysis for antiangiogenic factor IP-10
Blood serum from three mice from each group was collected 3 days after the sixth treatment from the K-BALB tumour bearing mice. Levels of IP-10 in the sample blood serum in triplicate were quantified using the Quantikine mouse IP-10/CXCL10 (R&D Systems)
Tumour regression by rSFV expressing IL-12 CP Chikkanna-Gowda et al immunoassay kit, according to the manufacturer's instructions. The absorbance of the samples was read at 450 nm.
Statistical analysis
The statistical significance of tumour size among the different experimental treatment groups was analysed by one-way ANOVA, using Tukey's multiple comparison post-test to compare the probability (P) value of each group with its appropriate control TNE-treated group. Kaplan-Meier survival curves were used to analyse the overall median survival of mice and survival proportions in each of the treatment groups. The P-value significance of the lung metastasized clonogenic colonies was analysed using Dunn's multiple comparison post-test. All the statistical analyses were performed using the GraphPad Prism 4 programme and a P-value less than 0.05 was considered significant.
